Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
SHSE:600129'
s Debt-to-Equity Range Over the Past 10 Years
Min: 1.08 Med: 1.51 Max: 4.03
Current: 1.54
During the past 13 years, the highest Debt-to-Equity Ratio of Chongqing Taiji Industry (Group) Co was 4.03. The lowest was 1.08. And the median was 1.51.
SHSE:600129's Debt-to-Equity is ranked worse than 93.1% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs SHSE:600129: 1.54
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Chongqing Taiji Industry (Group) Co Debt-to-Equity Related Terms
Chongqing Taiji Industry (Group) Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Taiji Industry (Group) Co Debt-to-Equity Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Chongqing Taiji Industry (Group) Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chongqing Taiji Industry (Group) Co Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chongqing Taiji Industry (Group) Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Chongqing Taiji Industry (Group) Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Taiji Industry (Group) Co (SHSE:600129) has a Debt-to-Equity of 1.54 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Chongqing Taiji Industry (Group) Co and its competitors. This is near median its historical median of 1.51. Over the past decade, Chongqing Taiji Industry (Group) Co's Debt-to-Equity has ranged from 1.08 to 4.03. According to the industry distribution chart, Chongqing Taiji Industry (Group) Co ranks #756 out of 812 companies in the Drug Manufacturers industry, placing it in the top 93.1%.
Is Chongqing Taiji Industry (Group) Co's Debt-to-Equity too high?
Chongqing Taiji Industry (Group) Co's current Debt-to-Equity of 1.54 is near median its 10-year median of 1.51. Over the past 10 years, this metric has ranged from a low of 1.08 to a high of 4.03. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Chongqing Taiji Industry (Group) Co's value of 1.54 is 450% above this industry median. Based on the distribution chart, Chongqing Taiji Industry (Group) Co ranks #756 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Chongqing Taiji Industry (Group) Co has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chongqing Taiji Industry (Group) Co's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Chongqing Taiji Industry (Group) Co ranks #756 out of 812 companies for Debt-to-Equity. This places Chongqing Taiji Industry (Group) Co in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Chongqing Taiji Industry (Group) Co's value of 1.54 is 450% above this benchmark. Historically, Chongqing Taiji Industry (Group) Co's own Debt-to-Equity has ranged from 1.08 to 4.03 over the past decade. While the company's 10-year median is 1.51 vs. the industry median of 0.28, Chongqing Taiji Industry (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chongqing Taiji Industry (Group) Co's current Debt-to-Equity of 1.54 is 450% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Chongqing Taiji Industry (Group) Co and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chongqing Taiji Industry (Group) Co's current Debt-to-Equity is 1.54, which is near median its own 10-year median of 1.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chongqing Taiji Industry (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Chongqing Taiji Industry (Group) Co (SHSE:600129) is currently considered Possible Value Trap. The stock's GF Value™ is ¥19.57, compared to a current price of ¥13.37 — trading 31.7% below its estimated fair value. The current Debt-to-Equity is 1.54, which is near median its 10-year median of 1.51 and 450% above the Drug Manufacturers industry median of 0.28. Chongqing Taiji Industry (Group) Co's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Chongqing Taiji Industry (Group) Co (SHSE:600129), the current Debt-to-Equity is 1.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chongqing Taiji Industry (Group) Co (SHSE:600129) Overvalued in 2026?
Based on GuruFocus' analysis, Chongqing Taiji Industry (Group) Co stock appears to be undervalued.
The current stock price of ¥13.37 is trading 31.7% below its estimated GF Value™ of ¥19.57.
GuruFocus considers Chongqing Taiji Industry (Group) Co to be Possible Value Trap.
Key valuation signals for SHSE:600129:
Debt-to-Equity: 1.54 (near median its 10-year median of 1.51)
GF Value™: ¥19.57 vs. price of ¥13.37 (31.7% below fair value)
Industry Position: 450% above the Drug Manufacturers median (#756 of 812)
No single metric tells the full story. See the SHSE:600129 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chongqing Taiji Industry (Group) Co Ltd is a China-based company engaged in the production and sales of Chinese and Western medicines. It is also engaged in the cultivation of medicinal herbs. Its products mainly include capsules, syrup, oral liquid, lyophilized series, tablets, infusion series, and injections. The company mainly conducts its business in domestic and overseas markets.
71GF Score
Get the complete analysis for SHSE:600129
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600129 has been successfully added to your 
